GlassScriptPhysician profile
Jarrett S Dodd
NPI 1780668848
$9,033.69
in general payments reported to CMS, 2019-2025
44 companies · $769 in 2025
The $769 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,491 · 2020: $506 · 2021: $1,407 · 2022: $1,860 · 2023: $1,566 · 2024: $1,434 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,712 · Entertainment: $56.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,712.19 |
| Entertainment | $56.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,569.04 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $702.60 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $607.16 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $583.80 | 2019-2023 | Xarelto |
| Abbvie INC. | $531.04 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $512.40 | 2019-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $467.49 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.32 | 2019-2025 | Jardiance |
| Pfizer INC. | $379.19 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $354.71 | 2020-2024 | Trintellix |
| Abbott Laboratories | $303.71 | 2019-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $282.04 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Amarin Pharma, INC. | $253.89 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $248.12 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.13 | 2019-2025 | Xifaxan |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $144.44 | 2021-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $143.70 | 2020-2022 | |
| Esperion Therapeutics, INC. | $127.53 | 2021-2025 | Nexletol |
| Astellas Pharma US INC | $127.37 | 2021-2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $124.01 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.72 | 2022-2025 | |
| Genentech USA, INC. | $90.04 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $85.54 | 2019-2023 | |
| Sanofi Pasteur INC. | $74.44 | 2019-2022 | |
| Eisai INC. | $69.56 | 2021 | |
| Xeris Pharmaceuticals, INC. | $61.64 | 2022-2023 | Gvoke Hypopen |
| Exact Sciences Corporation | $54.92 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $54.81 | 2022-2023 | Quviviq |
| Lundbeck LLC | $48.95 | 2024 | Rexulti |
| Insightec,INC | $42.62 | 2024 | Exablate |
| Ani Pharmaceuticals, INC. | $32.95 | 2025 | Purified Cortrophin Gel |
| Currax Pharmaceuticals LLC | $29.62 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $26.14 | 2021 | |
| Mylan Specialty L.P. | $21.76 | 2022 | |
| Nestle Healthcare Nutrition INC. | $19.19 | 2021 | |
| Organon LLC | $18.94 | 2022 | |
| Corium, LLC | $18.47 | 2023 | Adlarity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.32 | 2025 | Caplyta |
| Philips North America LLC | $18.08 | 2024 | (Ck6) Holter |
| Ultragenyx Pharmaceutical INC. | $16.04 | 2019 | |
| Inspire Medical Systems, INC. | $14.85 | 2025 | Inspire |
| Almatica Pharma LLC | $14.76 | 2021 | |
| Optos, INC. | $14.35 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Neurocrine Biosciences, INC. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jarrett Dodd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.